At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 61 enrolled
Drug / intervention
omalizumab +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lyophilized and Aged Liquid Omalizumab in the Prevention of Allergen-Induced Airway Obstruction in Adults With Mild Allergic Asthma
In Brief
A Phase 2 clinical trial evaluating omalizumab and placebo for Allergic Asthma. Completed, enrolled 61 participants.
Detailed Summary
This was a multicenter, randomized, double-blind, parallel-group, three-arm, placebo-controlled study designed to demonstrate the efficacy of two different formulations of omalizumab compared with placebo in reducing the airway reaction to an inhaled aeroallergen solution in adult subjects with mild allergic asthma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAllergic Asthma
Countries--
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 2007
Enrollment StartOct 2007
Primary CompletionFeb 2009
Study CompletionJun 2009
TodayJul 2026
First PostedFeb 13, 2007
Enrollment StartOct 1, 2007
Primary CompletionFeb 1, 2009
Study CompletionJun 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 19.4 years ago
Interventions
omalizumabdrug
Aged Liquid; subcutaneous repeating dose
omalizumabdrug
Lyophilized; subcutaneous repeating dose
placebodrug
Subcutaneous repeating dose